In recent weeks the FDA has begun facing an unexpectedly large number of applications that have not been processed This was partly due to a deadline for submitting applications that reflected required changes in testing medicines One industry expert however says the backlog reflects a more fundamental problem the FDA is having with the growing amount of paperwork and this threatens to derail agency goals to reduce outstanding requests to approve generic drugs